Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Virpax Pharmaceuticals, Inc. (VRPX) had Return on Tangible Equity of 1320.61% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-12.07M |
|
-- |
|
-- |
|
$12.08M |
|
$-12.08M |
|
$0.01M |
|
$-12.07M |
|
$-12.07M |
|
$-12.07M |
|
$-12.07M |
|
$-12.07M |
|
$-12.07M |
|
$-12.08M |
|
$-12.08M |
|
0.17M |
|
0.17M |
|
$-71.00 |
|
$-71.00 |
|
| Balance Sheet Financials | |
$1.56M |
|
-- |
|
-- |
|
$1.56M |
|
$2.47M |
|
-- |
|
-- |
|
$2.47M |
|
$-0.91M |
|
$-0.91M |
|
$-0.91M |
|
0.60M |
|
| Cash Flow Statement Financials | |
$-16.71M |
|
-- |
|
$9.08M |
|
$9.14M |
|
$1.51M |
|
$-7.63M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.63 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
1320.62% |
|
|
Return on Tangible Equity |
1320.61% |
-775.72% |
|
1320.61% |
|
$-1.53 |
|
$-98.21 |
|
$-98.21 |
|